GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » EV-to-EBITDA

EirGenix (ROCO:6589) EV-to-EBITDA : -35.39 (As of May. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is EirGenix EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EirGenix's enterprise value is NT$19,468 Mil. EirGenix's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-550 Mil. Therefore, EirGenix's EV-to-EBITDA for today is -35.39.

The historical rank and industry rank for EirGenix's EV-to-EBITDA or its related term are showing as below:

ROCO:6589' s EV-to-EBITDA Range Over the Past 10 Years
Min: -304.73   Med: -16.23   Max: 320.92
Current: -35.92

During the past 11 years, the highest EV-to-EBITDA of EirGenix was 320.92. The lowest was -304.73. And the median was -16.23.

ROCO:6589's EV-to-EBITDA is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 10.33 vs ROCO:6589: -35.92

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), EirGenix's stock price is NT$79.60. EirGenix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-2.680. Therefore, EirGenix's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


EirGenix EV-to-EBITDA Historical Data

The historical data trend for EirGenix's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EirGenix EV-to-EBITDA Chart

EirGenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.33 -11.91 155.40 305.80 -38.64

EirGenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -273.66 -94.20 -63.86 -38.64 -39.51

Competitive Comparison of EirGenix's EV-to-EBITDA

For the Biotechnology subindustry, EirGenix's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EirGenix's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EirGenix's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EirGenix's EV-to-EBITDA falls into.



EirGenix EV-to-EBITDA Calculation

EirGenix's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=19467.758/-550.12
=-35.39

EirGenix's current Enterprise Value is NT$19,468 Mil.
EirGenix's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-550 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EirGenix  (ROCO:6589) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

EirGenix's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=79.60/-2.680
=At Loss

EirGenix's share price for today is NT$79.60.
EirGenix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.680.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


EirGenix EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EirGenix's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


EirGenix (ROCO:6589) Business Description

Traded in Other Exchanges
N/A
Address
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.

EirGenix (ROCO:6589) Headlines

No Headlines